A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This study assesses the tolerability, safety, efficacy and pharmacokinetics of everolimus in
Japanese patients. Everolimus is administered orally everyday to adult patients with relapsed
or refractory non-Hodgkin's lymphoma who have progressed despite standard therapy or for whom
standard systemic therapy dose not exist.